39 related articles for article (PubMed ID: 33938693)
1. Rationale for Use of Micronized Isotretinoin for Treatment of Acne Vulgaris: Practical Considerations and Therapeutic Advantages.
Del Rosso JQ
J Clin Aesthet Dermatol; 2023 Sep; 16(9):20-24. PubMed ID: 37720199
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy.
Henry D; Dormuth C; Winquist B; Carney G; Bugden S; Teare G; Lévesque LE; Bérard A; Paterson JM; Platt RW;
CMAJ; 2016 Jul; 188(10):723-730. PubMed ID: 27114489
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy and isotretinoin therapy.
Dumont T; Black A
CMAJ; 2013 Apr; 185(6):508. PubMed ID: 23550056
[No Abstract] [Full Text] [Related]
4. Drug-cyclodextrin-vesicles dual carrier approach for skin targeting of anti-acne agent.
Kaur N; Puri R; Jain SK
AAPS PharmSciTech; 2010 Jun; 11(2):528-37. PubMed ID: 20333488
[TBL] [Abstract][Full Text] [Related]
5. An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period.
Del Rosso JQ; Stein Gold L; Segal J; Zaenglein AL
J Clin Aesthet Dermatol; 2019 Nov; 12(11):13-18. PubMed ID: 32038751
[No Abstract] [Full Text] [Related]
6. Development of immediate-release formulation with reliable absorption of rivaroxaban in various meal regimes.
Bosák J; Šíma M; Krejčí T; Obadalová I; Šmardová J; Kozlík P; Křížek T; Beránek J; Hauser T; Slanař O
Clin Transl Sci; 2024 May; 17(5):e13820. PubMed ID: 38738493
[TBL] [Abstract][Full Text] [Related]
7. Acne Vulgaris Relapse in Sudanese Patients Treated with Oral Isotretinoin: Rate and Predictive Factors.
Ibrahim S; Osman B; Awaad RM; Abdoon I
J Multidiscip Healthc; 2023; 16():839-849. PubMed ID: 37020969
[TBL] [Abstract][Full Text] [Related]
8. Oral Isotretinoin: New Developments Relevant to Clinical Practice.
Tan J; Boyal S; Desai K; Knezevic S
Dermatol Clin; 2016 Apr; 34(2):175-84. PubMed ID: 27015777
[TBL] [Abstract][Full Text] [Related]
9. Patient Perspectives: Treating acne with isotretinoin.
Pediatr Dermatol; 2015; 32(6):e324-5. PubMed ID: 26584707
[No Abstract] [Full Text] [Related]
10. ARTICLE: Advances in Oral Isotretinoin Therapy.
Jones M; Armstrong AW; Baldwin H; Stein Gold L; Kircik LH
J Drugs Dermatol; 2021 May; 20(5):s5-s11. PubMed ID: 33938693
[TBL] [Abstract][Full Text] [Related]
11. ABSORICA (isotretinoin): a new form.
Scheinfeld N
Skinmed; 2013; 11(2):117-9. PubMed ID: 23745231
[No Abstract] [Full Text] [Related]
12. Improving bioavailability with a novel isotretinoin formulation (isotretinoin-Lidose).
Tan J; Knezevic S
Skin Therapy Lett; 2013; 18(6):1-3. PubMed ID: 24305729
[TBL] [Abstract][Full Text] [Related]
13. Consensus Statements on the Use of Novel Formulations of Isotretinoin: A Modified Delphi Process.
Kingston P; Kircik L; Bhatia N; Del Rosso J; Desai SR; Harper JC; Gold LS; Hougeir F; Armstrong AW
J Drugs Dermatol; 2024 Jun; 23(6):429-432. PubMed ID: 38834212
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study.
Webster GF; Leyden JJ; Gross JA
J Am Acad Dermatol; 2013 Nov; 69(5):762-767. PubMed ID: 23953888
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
